Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study

Kiran Naqvi, Naval Daver, Naveen Pemmaraju, Prithviraj Bose, Guillermo Garcia-Manero, Jorge Cortes, Hagop M. Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticle

Abstract

Ruxolitinib is the only approved therapy for myelofibrosis (MF). However, its use in patients with myeloproliferative neoplasms (MPN) not participating in clinical studies has been poorly described. We reviewed the medical records of 45 patients (35 MF, 10 others) treated with ruxolitinib at our center, off clinical study, during the year after its approval. Patients had advanced features and were refractory to multiple therapies. Ruxolitinib was effective in reducing splenomegaly (51% response rate) and constitutional symptoms (42% response rate). It controlled blood counts in patients with polycythemia and thrombocythemia but was not effective in patients with non-classic MPNs. Ruxolitinib was an active therapy in patients previously treated with a JAK inhibitor and was safely combined with hypomethylating agents in patients with elevated blasts. Median overall survival was 24 months; 10 patients transformed to acute leukemia. Its use in combination with other active agents should be further explored in clinical studies.

Original languageEnglish (US)
Pages (from-to)866-871
Number of pages6
JournalLeukemia and Lymphoma
Volume58
Issue number4
DOIs
StatePublished - Apr 3 2017
Externally publishedYes

Fingerprint

Neoplasms
Primary Myelofibrosis
Thrombocytosis
Polycythemia
Splenomegaly
Proxy
INCB018424
Clinical Studies
Medical Records
Leukemia
Therapeutics
Survival

Keywords

  • Myelofibrosis
  • myeloproliferative neoplasms
  • ruxolitinib
  • splenomegaly

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. / Naqvi, Kiran; Daver, Naval; Pemmaraju, Naveen; Bose, Prithviraj; Garcia-Manero, Guillermo; Cortes, Jorge; Kantarjian, Hagop M.; Verstovsek, Srdan.

In: Leukemia and Lymphoma, Vol. 58, No. 4, 03.04.2017, p. 866-871.

Research output: Contribution to journalArticle

Naqvi, Kiran ; Daver, Naval ; Pemmaraju, Naveen ; Bose, Prithviraj ; Garcia-Manero, Guillermo ; Cortes, Jorge ; Kantarjian, Hagop M. ; Verstovsek, Srdan. / Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. In: Leukemia and Lymphoma. 2017 ; Vol. 58, No. 4. pp. 866-871.
@article{805662f1f5e74419bb19ec7a78c11223,
title = "Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study",
abstract = "Ruxolitinib is the only approved therapy for myelofibrosis (MF). However, its use in patients with myeloproliferative neoplasms (MPN) not participating in clinical studies has been poorly described. We reviewed the medical records of 45 patients (35 MF, 10 others) treated with ruxolitinib at our center, off clinical study, during the year after its approval. Patients had advanced features and were refractory to multiple therapies. Ruxolitinib was effective in reducing splenomegaly (51{\%} response rate) and constitutional symptoms (42{\%} response rate). It controlled blood counts in patients with polycythemia and thrombocythemia but was not effective in patients with non-classic MPNs. Ruxolitinib was an active therapy in patients previously treated with a JAK inhibitor and was safely combined with hypomethylating agents in patients with elevated blasts. Median overall survival was 24 months; 10 patients transformed to acute leukemia. Its use in combination with other active agents should be further explored in clinical studies.",
keywords = "Myelofibrosis, myeloproliferative neoplasms, ruxolitinib, splenomegaly",
author = "Kiran Naqvi and Naval Daver and Naveen Pemmaraju and Prithviraj Bose and Guillermo Garcia-Manero and Jorge Cortes and Kantarjian, {Hagop M.} and Srdan Verstovsek",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/10428194.2016.1217528",
language = "English (US)",
volume = "58",
pages = "866--871",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study

AU - Naqvi, Kiran

AU - Daver, Naval

AU - Pemmaraju, Naveen

AU - Bose, Prithviraj

AU - Garcia-Manero, Guillermo

AU - Cortes, Jorge

AU - Kantarjian, Hagop M.

AU - Verstovsek, Srdan

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Ruxolitinib is the only approved therapy for myelofibrosis (MF). However, its use in patients with myeloproliferative neoplasms (MPN) not participating in clinical studies has been poorly described. We reviewed the medical records of 45 patients (35 MF, 10 others) treated with ruxolitinib at our center, off clinical study, during the year after its approval. Patients had advanced features and were refractory to multiple therapies. Ruxolitinib was effective in reducing splenomegaly (51% response rate) and constitutional symptoms (42% response rate). It controlled blood counts in patients with polycythemia and thrombocythemia but was not effective in patients with non-classic MPNs. Ruxolitinib was an active therapy in patients previously treated with a JAK inhibitor and was safely combined with hypomethylating agents in patients with elevated blasts. Median overall survival was 24 months; 10 patients transformed to acute leukemia. Its use in combination with other active agents should be further explored in clinical studies.

AB - Ruxolitinib is the only approved therapy for myelofibrosis (MF). However, its use in patients with myeloproliferative neoplasms (MPN) not participating in clinical studies has been poorly described. We reviewed the medical records of 45 patients (35 MF, 10 others) treated with ruxolitinib at our center, off clinical study, during the year after its approval. Patients had advanced features and were refractory to multiple therapies. Ruxolitinib was effective in reducing splenomegaly (51% response rate) and constitutional symptoms (42% response rate). It controlled blood counts in patients with polycythemia and thrombocythemia but was not effective in patients with non-classic MPNs. Ruxolitinib was an active therapy in patients previously treated with a JAK inhibitor and was safely combined with hypomethylating agents in patients with elevated blasts. Median overall survival was 24 months; 10 patients transformed to acute leukemia. Its use in combination with other active agents should be further explored in clinical studies.

KW - Myelofibrosis

KW - myeloproliferative neoplasms

KW - ruxolitinib

KW - splenomegaly

UR - http://www.scopus.com/inward/record.url?scp=84982786659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982786659&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1217528

DO - 10.1080/10428194.2016.1217528

M3 - Article

C2 - 27494751

AN - SCOPUS:84982786659

VL - 58

SP - 866

EP - 871

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -